Compounds > quinoxalines
Page last updated: 2024-08-17

quinoxalines and cyclin d1

quinoxalines has been researched along with cyclin d1 in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's6 (85.71)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cardesa, A; Dasenbrock, C; Fernandez, PL; Mohr, U; Palacín, A; Pera, M; Tillman, T1
Hobbs, AJ; Khambata, RS; Panayiotou, CM1
Dong, MS; Gong, YD; Lee, SB; Park, YI1
Debnath, B; Garofalo, A; Grande, F; Imada, T; Masuda, M; Neamati, N; Oshima, T; Xu, S1
Ishii, Y; Jin, M; Kijima, A; Kodama, Y; Kuroda, K; Matsushita, K; Takasu, S; Umemura, T1
Aiello, F; Bruno, A; Carullo, G; Costantino, G; Garofalo, A; Giordano, F; Nigro, A; Radi, M; Spina, E; Tassini, S; Vincetti, P1
Arteaga, CL; Balko, JM; Bardia, A; Bauer, JA; Behdad, A; Cristofanilli, M; Croessmann, S; Cruz, MR; Dugger, TC; Ericsson, PG; Formisano, L; Guerrero-Zotano, AL; Guo, Y; Hanker, AB; He, W; Jansen, VM; Lanman, RB; Lee, KM; Lu, Y; Mayer, IA; Miller, M; Nagy, RJ; Nixon, MJ; O'Shaughnessy, J; Sanders, ME; Schwarz, LJ; Servetto, A; Shyr, Y; Solovieff, N; Su, F; Sudhan, DR1

Other Studies

7 other study(ies) available for quinoxalines and cyclin d1

ArticleYear
Expression of cyclin D1 and p53 and its correlation with proliferative activity in the spectrum of esophageal carcinomas induced after duodenal content reflux and 2,6-dimethylnitrosomorpholine administration in rats.
    Carcinogenesis, 2001, Volume: 22, Issue:2

    Topics: Adenocarcinoma; Animals; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Cell Division; Cyclin D1; Duodenogastric Reflux; Esophageal Neoplasms; Esophagectomy; Female; Immunoenzyme Techniques; Jejunostomy; Ki-67 Antigen; Male; Quinoxalines; Rats; Rats, Sprague-Dawley; Tumor Suppressor Protein p53

2001
Natriuretic peptide receptor-3 underpins the disparate regulation of endothelial and vascular smooth muscle cell proliferation by C-type natriuretic peptide.
    British journal of pharmacology, 2011, Volume: 164, Issue:2b

    Topics: Animals; Aorta; Cell Cycle Proteins; Cell Growth Processes; Cells, Cultured; Cyclic GMP; Cyclin D1; Endothelial Cells; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice; Mice, Knockout; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Natriuretic Peptide, C-Type; Oligopeptides; Phosphorylation; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Atrial Natriuretic Factor; Signal Transduction

2011
2,3,6-Trisubstituted quinoxaline derivative, a small molecule inhibitor of the Wnt/beta-catenin signaling pathway, suppresses cell proliferation and enhances radiosensitivity in A549/Wnt2 cells.
    Biochemical and biophysical research communications, 2013, Feb-22, Volume: 431, Issue:4

    Topics: Antineoplastic Agents; beta Catenin; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Cyclin D1; Humans; Lung Neoplasms; Quinoxalines; Radiation Tolerance; Radiation-Sensitizing Agents; Respiratory Mucosa; Wnt Proteins; Wnt Signaling Pathway

2013
Stabilization of MDA-7/IL-24 for colon cancer therapy.
    Cancer letters, 2013, Jul-28, Volume: 335, Issue:2

    Topics: Aged; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Cyclin D1; Down-Regulation; fas Receptor; Female; G1 Phase Cell Cycle Checkpoints; Humans; Hydrazines; Interleukins; Male; Molecular Docking Simulation; Prognosis; Quinoxalines; Recombinant Proteins; Survival; Tumor Suppressor Protein p53; Up-Regulation

2013
Flumequine enhances the in vivo mutagenicity of MeIQx in the mouse liver.
    Archives of toxicology, 2013, Volume: 87, Issue:8

    Topics: Animals; Body Weight; Cell Proliferation; Cyclin D1; Cytochrome P-450 CYP1A2; Drug Synergism; Fluoroquinolones; Glucuronosyltransferase; Hepatocytes; Liver; Male; Mice; Mice, Transgenic; Mutagens; Mutation; Oligonucleotide Array Sequence Analysis; Phenobarbital; Quinoxalines

2013
Identification of Breast Cancer Inhibitors Specific for G Protein-Coupled Estrogen Receptor (GPER)-Expressing Cells.
    ChemMedChem, 2017, 08-22, Volume: 12, Issue:16

    Topics: Antineoplastic Agents; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Estrogen Receptor alpha; Estrogen Receptor beta; Female; HEK293 Cells; Humans; MCF-7 Cells; Molecular Docking Simulation; Protein Structure, Tertiary; Quinoxalines; Receptors, G-Protein-Coupled; Tumor Suppressor Protein p53

2017
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.
    Nature communications, 2019, 03-26, Volume: 10, Issue:1

    Topics: Aminopyridines; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Circulating Tumor DNA; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Female; Fulvestrant; High-Throughput Nucleotide Sequencing; Humans; MCF-7 Cells; Mice; Mutation; Naphthalenes; Piperazines; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridines; Quinolines; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Receptors, Estrogen; Signal Transduction; Xenograft Model Antitumor Assays

2019